🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS · Phase II

Neurology & CNS programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
230

Quick answer

Neurology & CNS Phase II programs: NovaPharmaNews indexes 230 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 2 of 5

  1. CT1812

    COGNITION THERAPEUTICS INC

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  2. CT1812

    COGNITION THERAPEUTICS INC

    Early Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  3. CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  4. CX-8998

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  5. CX-8998

    Jazz Pharmaceuticals Ireland Limited

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  6. Cannabidiol Capsules, Füllstoffmischung DAC in hardshell gelatine capsules, size 1, is used as placebo. Füllstoffmischung DAC consists of mannitol 99.5 % and silloidal silicon dioxide (Aerosil®) 0.5 %.

    The George Institute

    Remitted early phase schizophrenia

    phase 2 small molecule active

    1 trial

  7. Clonazepam

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  8. DAAOI-P

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease With Dementia

    phase 2 small molecule completed

    1 trial

  9. DMTs + taurine

    The First People's Hospital of Lianyungang

    Multiple Sclerosis (MS) Relapsing Remitting

    phase 2 small molecule active

    1 trial

  10. Dexmedetomidine

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  11. Diazepam Buccal Film

    Aquestive Therapeutics

    Epilepsy

    phase 2 small molecule completed

    2 trials

  12. Diazepam Buccal Film 12.5 mg

    Aquestive Therapeutics

    Epilepsy

    phase 2 small molecule completed

    1 trial

  13. Diphenhydramine Hydrochloride Tablets 50 mg, Paracetamol 500mg Tablets, Ocrevus 300 mg concentrate for solution for infusion, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis (RRMS)

    phase 2 small molecule active

    1 trial

  14. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  15. Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 other active

    1 trial

  16. Everolimus

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  17. Exercise Programme

    United Therapeutics Europe Ltd

    Parkinson's Disease

    phase 2 other completed

    1 trial

  18. FLORBETAPIR, Placebo to match LY, Flortaucipir, Donanemab

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  19. Florquinitau F-18, Sodium Chloride, PRX005

    Bristol-Myers Squibb Australia Pty Ltd

    Early Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  20. Flortaucipir, Placebo to match LY3372689

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  21. Fluoxetine

    The First People's Hospital of Lianyungang

    Depression

    phase 2 small molecule active

    1 trial

  22. Fycompa 2 mg film-coated tablets, Fycompa 2 mg film-coated tablets, Fycompa 0.5 mg/ml oral suspension, Fycompa 2 mg film-coated tablets

    Eisai Co.,

    Childhood Epilepsy

    phase 2 small molecule active

    1 trial

  23. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  24. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  25. GWP42003-P 5 mg/kg/day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  26. GWP42006

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    2 trials

  27. GXV813, GXV813, Placebo 0 mg Hard gelatin capsule

    Novartis Pharmaceuticals

    Schizophrenia

    phase 2 small molecule active

    1 trial

  28. Glatiramer Acetate, N-Acetylcysteine

    Teva Pharma GmbH

    Relapse Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  29. GlyT-1 inhibitor-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  30. Green Tea Polyphenols (EGCG/ECG)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  31. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Parkinson Disease Psychosis

    phase 2 small molecule terminated

    1 trial

  32. Iloperidone crystalline formulation

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  33. Insulin

    United Therapeutics Europe Ltd

    Multiple Sclerosis, Relapsing-Remitting

    phase 2 small molecule completed

    1 trial

  34. K0706

    Advanced Accelerator Applications

    Early Parkinson Disease

    phase 2 small molecule terminated

    1 trial

  35. KALINOX 50%/50%, gaz medicinal comprime, Medical Air

    Tour Hekla

    psychiatry

    phase 2 small molecule active

    1 trial

  36. KYV-101

    Kyverna Therapeutics

    Multiple Sclerosis, Primary Progressive

    phase 2 mab active

    1 trial

  37. Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThe

    Kyverna Therapeutics

    Primary or Secondary Progressive Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  38. Ketamine Hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  39. LX1001

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 mab completed

    1 trial

  40. LY2140023

    Novo Nordisk A/S

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  41. Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG

    MEDA Pharma GmbH & Co. KG

    Mild Cognitive impairment due to Alzheimer Disease

    phase 2 small molecule active

    1 trial

  42. Laquinimod 0.6

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

  43. Leuprolide acetate

    Voyager Therapeutics

    Alzheimer Disease

    phase 2 small molecule completed

    2 trials

  44. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  45. Low Dose GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  46. Lu AA34893

    H. Lundbeck A/S

    Depression in Patients With Bipolar Disorder

    phase 2 small molecule terminated

    1 trial

  47. Lu AE58054

    H. Lundbeck A/S

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  48. Luvadaxistat

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule completed

    2 trials

Frequently asked questions

How many neurology & cns Phase II programs exist?

230 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.